VEGF-B Inhibitors
1 drugsAbout VEGF-B
Vascular Endothelial Growth Factor B (VEGF-B) is a protein involved in angiogenesis and vascular permeability. As a member of the VEGF family, it has been implicated in tumor growth and metastasis, making it a target of interest in oncology.
VEGF-B is explored as a therapeutic target to disrupt the blood supply fueling tumor growth. Currently, there is no genetic evidence available linking VEGF-B to specific diseases, highlighting an area for future investigation.
VEGF-B is targeted by one FDA-approved drug, ZALTRAP (a fusion protein), developed by Sanofi for oncology indications. Further research is needed to fully elucidate VEGF-B's role and therapeutic potential.
Top VEGF-B Drugs
Sanofi is the only company with an approved drug targeting VEGF-B.
Limited competition presents an opportunity for new entrants, but also indicates potential challenges.
VEGF-B Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets VEGF-B, using fusion protein modality.
Explore alternative modalities like antibodies or small molecules to diversify the therapeutic approach.
VEGF-B Clinical Trials 308 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on VEGF-B. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 40 | 27 | 7 | 5 | 79% |
| Phase 2 | 96 | 60 | 19 | 17 | 76% |
| Phase 3 | 99 | 56 | 13 | 30 | 81% |
| Phase 4 | 73 | 56 | 9 | 8 | 86% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
VEGF-B Drug Approval Timeline (2012 - 2012)
The first and only drug, ZALTRAP, was approved in 2012.
The lack of recent approvals suggests a saturated market or challenges in developing new VEGF-B inhibitors.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 158 (51 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on VEGF-B. A trial counts if an approved drug acting on VEGF-B is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.